New Drug Approvals (Original) — July 14, 2026

Sanofi-Aventis U.S. LLC received FDA NME approval for ISATUXIMAB-IRFC (SARCLISA ESCENA) with Orphan Drug designation, signaling a potential new multiple myeloma therapy with 7-year market exclusivity and premium pricing potential ($100K-500K+/yr).

Provipharm SAS received label expansion approval for INDOCYANINE GREEN INJECTION (ZYOGREEN), a diagnostic dye used in ophthalmic and hepatic imaging, expanding its addressable market.

Amneal EU Ltd received label expansion approval for SODIUM BICARBONATE, a widely used electrolyte for metabolic acidosis, potentially broadening its clinical use.

Ajanta Pharma's biosimilar approval for METFORMIN HYDROCHLORIDE, SITAGLIPTIN (Janumet) increases generic competition in the DPP-4 inhibitor/metformin combination market, pressuring originator Merck's pricing and market share.

Laurus Labs' biosimilar approval for TENOFOVIR ALAFENAMIDE FUMARATE (Vemlidy) adds generic competition to Gilead's hepatitis B and HIV drug, potentially reducing Gilead's revenue.

Glenmark's biosimilar approval for NINTEDANIB ESYLATE (Ofev) threatens Boehringer Ingelheim's idiopathic pulmonary fibrosis drug, with potential 30-60% revenue erosion over 2-3 years.

Baxter's biosimilar approval for EPHEDRINE SULFATE adds competition to the vasopressor market, though impact is limited due to low-cost generic nature.

Aspiro's biosimilar approval for CYANOCOBALAMIN (vitamin B12) and Macleods' biosimilar approval for DAPSONE (antibacterial) add to already crowded generic markets, with limited differentiation.

Sanofi's ISATUXIMAB-IRFC (SARCLISA ESCENA) launch in multiple myeloma, leveraging Orphan Drug exclusivity and potential combination with standard-of-care therapies (e.g., daratumumab, pomalidomide).

Provipharm's ZYOGREEN label expansion could capture additional diagnostic imaging procedures, though market size is likely small.

Ajanta Pharma's entry into the metformin/sitagliptin combination market could capture share from Merck's Janumet, especially if priced competitively.

Multiple approvals for generics/biosimilars targeting diabetes (metformin/sitagliptin), hepatitis B/HIV (tenofovir alafenamide), and idiopathic pulmonary fibrosis (nintedanib) signal increasing competition in chronic disease markets.

Sanofi's ISATUXIMAB-IRFC approval highlights continued interest in orphan oncology, with potential for premium pricing and targeted patient populations.

{"entity"=>"ISATUXIMAB-IRFC (Sanofi)", "reason"=>"NME approval with Orphan designation; launch strategy and clinical data will determine commercial success.", "trigger"=>"Launch date, payer coverage decisions, and Phase 3 trial readouts for combination regimens"}

{"entity"=>"NINTEDANIB ESYLATE (Glenmark vs. Boehringer Ingelheim)", "reason"=>"Biosimilar entry threatens Ofev's $3B+ franchise; patent litigation and launch timing are key.", "trigger"=>"Biosimilar launch date, patent settlement or court ruling"}

{"entity"=>"TENOFOVIR ALAFENAMIDE FUMARATE (Laurus Labs vs. Gilead)", "reason"=>"Generic entry could accelerate Vemlidy revenue decline; monitor pricing and market share.", "trigger"=>"Launch timing and payer adoption"}